Akoya Biosciences, Inc. (AKYA)
NASDAQ: AKYA · Real-Time Price · USD
1.430
-0.060 (-4.03%)
At close: Mar 28, 2025, 4:00 PM
1.427
-0.003 (-0.21%)
After-hours: Mar 28, 2025, 7:15 PM EDT
Akoya Biosciences Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Akoya Biosciences stock have an average target of 3.26, with a low estimate of 1.80 and a high estimate of 5.00. The average target predicts an increase of 127.97% from the current stock price of 1.43.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Akoya Biosciences stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 2 | 2 | 2 | 1 |
| Buy | 2 | 1 | 1 | 1 | 1 | 1 |
| Hold | 4 | 5 | 5 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 8 | 8 | 8 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stephens & Co. | Stephens & Co. | Buy → Hold Downgrades $3.5 → $1.8 | Buy → Hold | Downgrades | $3.5 → $1.8 | +25.87% | Mar 25, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $3.5 | Buy | Reiterates | $3.5 | +144.76% | Mar 18, 2025 |
| Piper Sandler | Piper Sandler | Buy Reiterates $4 → $3 | Buy | Reiterates | $4 → $3 | +109.79% | Nov 19, 2024 |
| Craig-Hallum | Craig-Hallum | Strong Buy → Hold Downgrades $7 → $5 | Strong Buy → Hold | Downgrades | $7 → $5 | +249.65% | Nov 15, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $6 → $3.5 | Strong Buy | Maintains | $6 → $3.5 | +144.76% | Nov 15, 2024 |
Financial Forecast
Revenue This Year
93.42M
from 81.67M
Increased by 14.38%
Revenue Next Year
107.46M
from 93.42M
Increased by 15.03%
EPS This Year
-0.63
from -1.12
EPS Next Year
-0.46
from -0.63
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 98.7M | 117.6M | 133.0M | ||
| Avg | 93.4M | 107.5M | 113.1M | ||
| Low | 87.2M | 90.7M | 93.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 20.8% | 25.9% | 23.8% | ||
| Avg | 14.4% | 15.0% | 5.3% | ||
| Low | 6.8% | -2.9% | -13.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.46 | -0.36 | -0.43 | ||
| Avg | -0.63 | -0.46 | -0.47 | ||
| Low | -0.70 | -0.54 | -0.50 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.